Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study

Gabriel Brisou, Jérôme Paillassa, Sophie Bernard, Olivier Tournilhac, Luc-Matthieu Fornecker, Frédéric Maloisel, Lauris Gastaud, Eric Durot, Adrian Tempescul, Thorsten Braun, Vadim Ivanov, Brieuc Cherel, Caroline Serrier, Jeremy Delage, Abderrazak El Yamani, Baptiste Delapierre, Laure Lebras, Elsa Lestang, Camille Villesuzanne, Philippe Agape, Guillaume Escure, Ludovic Fouillet, Christophe Nicol, Gaëlle Olivier, Anthony Levy, Anne-Sophie Le Bris, Ophélie Cassuto, Laura Jacquemelle, Corinne Haioun, Charles Herbaux

Open source

DOI: 10.3324/haematol.2024.287141
Published: 2025-05-15
Container: Haematologica
Publisher: Ferrata Storti Foundation (Haematologica)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2024.287141,
  title = {Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study},
  author = {Gabriel Brisou and Jérôme Paillassa and Sophie Bernard and Olivier Tournilhac and Luc-Matthieu Fornecker and Frédéric Maloisel and Lauris Gastaud and Eric Durot and Adrian Tempescul and Thorsten Braun and Vadim Ivanov and Brieuc Cherel and Caroline Serrier and Jeremy Delage and Abderrazak El Yamani and Baptiste Delapierre and Laure Lebras and Elsa Lestang and Camille Villesuzanne and Philippe Agape and Guillaume Escure and Ludovic Fouillet and Christophe Nicol and Gaëlle Olivier and Anthony Levy and Anne-Sophie Le Bris and Ophélie Cassuto and Laura Jacquemelle and Corinne Haioun and Charles Herbaux},
  year = {2025},
  journal = {Haematologica},
  doi = {10.3324/haematol.2024.287141},
  url = {https://doi.org/10.3324/haematol.2024.287141}
}

RIS

TY  - JOUR
TI  - Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study
AU  - Gabriel Brisou
AU  - Jérôme Paillassa
AU  - Sophie Bernard
AU  - Olivier Tournilhac
AU  - Luc-Matthieu Fornecker
AU  - Frédéric Maloisel
AU  - Lauris Gastaud
AU  - Eric Durot
AU  - Adrian Tempescul
AU  - Thorsten Braun
AU  - Vadim Ivanov
AU  - Brieuc Cherel
AU  - Caroline Serrier
AU  - Jeremy Delage
AU  - Abderrazak El Yamani
AU  - Baptiste Delapierre
AU  - Laure Lebras
AU  - Elsa Lestang
AU  - Camille Villesuzanne
AU  - Philippe Agape
AU  - Guillaume Escure
AU  - Ludovic Fouillet
AU  - Christophe Nicol
AU  - Gaëlle Olivier
AU  - Anthony Levy
AU  - Anne-Sophie Le Bris
AU  - Ophélie Cassuto
AU  - Laura Jacquemelle
AU  - Corinne Haioun
AU  - Charles Herbaux
PY  - 2025
JO  - Haematologica
DO  - 10.3324/haematol.2024.287141
UR  - https://doi.org/10.3324/haematol.2024.287141
ER  -

APA

Brisou, G., Paillassa, J., Bernard, S., Tournilhac, O., Fornecker, L., Maloisel, F., Gastaud, L., Durot, E., Tempescul, A., Braun, T., Ivanov, V., Cherel, B., Serrier, C., Delage, J., Yamani, A. E., Delapierre, B., Lebras, L., Lestang, E., Villesuzanne, C., Agape, P., Escure, G., Fouillet, L., Nicol, C., Olivier, G., Levy, A., Bris, A. L., Cassuto, O., Jacquemelle, L., Haioun, C., & Herbaux, C. (2025). Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study. Haematologica. https://doi.org/10.3324/haematol.2024.287141

Source records

crossref · retrieved 2026-09-26T09:45:27.391Z